The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Advanced Drainage Systems, Inc. | Common | 00790R104 | 546,186 | 6,486 | SH | OTR | 6,486 | 0 | 0 | ||
Aptinyx, Inc. | Common | 03836N103 | 649,273 | 5,395,996 | SH | SOLE | 5,395,996 | 0 | 0 | ||
Confluent, Inc. | Common-Class A | 20717M103 | 491,172 | 20,406 | SH | OTR | 20,406 | 0 | 0 | ||
Corvus Pharmaceuticals, Inc. | Common | 221015100 | 2,980,811 | 3,275,616 | SH | SOLE | 3,275,616 | 0 | 0 | ||
Freshworks Inc. | Common- Class A | 358054104 | 157,594 | 10,260 | SH | OTR | 10,260 | 0 | 0 | ||
Fusion Pharmaceuticals, Inc. | Common | 36118A100 | 11,113,240 | 2,947,809 | SH | SOLE | 2,947,809 | 0 | 0 | ||
HashiCorp, Inc. | Common- Class A | 418100103 | 1,694,573 | 57,855 | SH | OTR | 57,855 | 0 | 0 | ||
Icosavax, Inc. | Common | 45114M109 | 12,879,950 | 2,220,681 | SH | SOLE | 2,220,681 | 0 | 0 | ||
Mineralys Therapeutics, Inc. | Common | 603170101 | 37,889,385 | 2,419,501 | SH | SOLE | 2,419,501 | 0 | 0 | ||
Paylocity Holding Corporation | Common | 70438V106 | 117,916,296 | 593,200 | SH | SOLE | 593,200 | 0 | 0 | ||
Q2 Holdings, Inc. | Common | 74736L109 | 19,143,576 | 777,562 | SH | SOLE | 777,562 | 0 | 0 | ||
Rimini Street, Inc. | Common | 76674Q107 | 97,089,584 | 23,565,433 | SH | SOLE | 23,565,433 | 0 | 0 | ||
Vacasa, Inc. | Common- Class A | 91854V107 | 18,013,921 | 18,764,501 | SH | SOLE | 18,764,501 | 0 | 0 |